WoodTrust Financial Corp Buys 400 Shares of ResMed Inc. (NYSE:RMD)

WoodTrust Financial Corp boosted its holdings in shares of ResMed Inc. (NYSE:RMD) by 6.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,020 shares of the medical equipment provider’s stock after buying an additional 400 shares during the period. WoodTrust Financial Corp’s holdings in ResMed were worth $1,390,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in RMD. Norges Bank bought a new stake in ResMed during the fourth quarter valued at $233,966,000. Morgan Stanley lifted its stake in ResMed by 102.4% during the third quarter. Morgan Stanley now owns 2,329,618 shares of the medical equipment provider’s stock worth $344,481,000 after purchasing an additional 1,178,547 shares during the last quarter. LGT Capital Partners LTD. bought a new stake in ResMed during the fourth quarter worth about $117,621,000. Los Angeles Capital Management LLC lifted its stake in ResMed by 3,599.0% during the first quarter. Los Angeles Capital Management LLC now owns 499,031 shares of the medical equipment provider’s stock worth $98,823,000 after purchasing an additional 485,540 shares during the last quarter. Finally, Greenvale Capital LLP lifted its stake in ResMed by 198.3% during the fourth quarter. Greenvale Capital LLP now owns 551,901 shares of the medical equipment provider’s stock worth $94,938,000 after purchasing an additional 366,901 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

ResMed Trading Down 0.1 %

NYSE:RMD traded down $0.16 during mid-day trading on Friday, reaching $191.42. 3,500,754 shares of the company’s stock traded hands, compared to its average volume of 1,291,510. ResMed Inc. has a 12-month low of $132.24 and a 12-month high of $229.97. The firm has a market capitalization of $28.12 billion, a price-to-earnings ratio of 29.40, a PEG ratio of 1.88 and a beta of 0.68. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.04 and a quick ratio of 1.97. The company has a 50 day moving average price of $208.47 and a 200-day moving average price of $191.10.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.22. ResMed had a return on equity of 24.43% and a net margin of 20.91%. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the business earned $1.68 EPS. ResMed’s revenue was up 7.2% compared to the same quarter last year. On average, sell-side analysts predict that ResMed Inc. will post 7.7 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 13th. Shareholders of record on Thursday, May 9th were given a dividend of $0.48 per share. The ex-dividend date was Wednesday, May 8th. This represents a $1.92 annualized dividend and a yield of 1.00%. ResMed’s payout ratio is 29.49%.

Insider Buying and Selling at ResMed

In other ResMed news, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $216.50, for a total transaction of $3,178,869.50. Following the sale, the chief executive officer now directly owns 440,752 shares of the company’s stock, valued at approximately $95,422,808. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other ResMed news, CFO Brett Sandercock sold 1,000 shares of ResMed stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $209.81, for a total transaction of $209,810.00. Following the sale, the chief financial officer now directly owns 91,056 shares of the company’s stock, valued at approximately $19,104,459.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael J. Farrell sold 14,683 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $216.50, for a total value of $3,178,869.50. Following the completion of the sale, the chief executive officer now directly owns 440,752 shares in the company, valued at $95,422,808. The disclosure for this sale can be found here. In the last three months, insiders have sold 31,151 shares of company stock valued at $6,666,409. 1.21% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on RMD. Mizuho reaffirmed a “buy” rating and set a $215.00 price target on shares of ResMed in a research note on Wednesday, March 27th. Oppenheimer lowered ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday. KeyCorp lifted their price target on ResMed from $227.00 to $238.00 and gave the stock an “overweight” rating in a research note on Friday, April 26th. Royal Bank of Canada lifted their price objective on ResMed from $187.00 to $200.00 and gave the stock a “sector perform” rating in a report on Friday, April 26th. Finally, Citigroup downgraded ResMed from a “buy” rating to a “neutral” rating in a report on Monday, June 24th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, ResMed has an average rating of “Moderate Buy” and an average price target of $202.80.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.